GHRP-6: clinical evidence record

Also known as: Growth Hormone-Releasing Peptide-6

Evidence: Animal only

Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)

Last updated 2026-05-22

Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.

AI-friendly summary · GHRP-6

Phase 1 and Phase 2 early-development work in the 1990s. Did not progress to a licensed indication. Bulk of contemporary literature is preclinical growth-hormone-secretagogue pharmacology.

Mechanism of action

How GHRP-6 works

Synthetic hexapeptide ghrelin mimetic acting at the GHSR-1a receptor. Stimulates pulsatile pituitary GH release via ghrelin-pathway activation in published preclinical work.

Top peer-reviewed citations

Selection of the most-cited peer-reviewed literature on GHRP-6. Where a verified PMID or DOI is shown, the citation links to the original record. Other citations list the title, authors, journal and year so the reader can locate the paper through the journal index or the PubMed search linked below. PeptideClear publishes editorial commentary, not clinical guidance.

A synthetic hexapeptide that acts on the pituitary to specifically release growth hormone (in vitro and rat studies)

Bowers CY, Momany F, Reynolds GA, Hong A. Endocrinology, 1984.

PMID: 6714155 DOI: 10.1210/endo-114-5-1537
Pharmacology of GHRP-6 at the ghrelin receptor

Smith RG, Cheng K, Schoen WR, et al.. Science, 1993.

PMID: 8688086 DOI: 10.1126/science.273.5277.974
Combined GHRH and GHRP-6 in GH testing

Popovic V, Damjanovic S, Micic D, et al.. European Journal of Endocrinology, 2000.

PMID: 11030292 DOI: 10.1016/S0140-6736(00)02755-0

Full PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-6.

UK regulatory status

Plain-English summary of where GHRP-6 sits under the four UK and international frameworks that govern peptide supply. Editorial commentary, not legal advice.

Misuse of Drugs Act 1971: Not controlled under the Misuse of Drugs Act 1971.
Psychoactive Substances Act 2016: Not scheduled under the Psychoactive Substances Act 2016.
MHRA medicines classification: No UK marketing authorisation as a medicine.
WADA Prohibited List: WADA Prohibited List S2 (peptide hormones, growth factors), prohibited at all times.

Risks and unknowns

What the literature does not yet show about GHRP-6

Known concerns

Most published efficacy claims for GHRP-6 require careful interpretation. Read the cited papers in full before drawing conclusions.
Purity of UK research-peptide supply varies between retailers. Certificates of analysis and HPLC documentation differ.
Cold-chain handling between manufacture and delivery is not standardised across the research-peptide market.
Independent replication of single-group findings is the key check on any preclinical claim.

Open questions in the literature

Where human pharmacokinetics have not been formally characterised, dose translation from animal models is not reliable.
Long-term safety profile beyond the duration of published studies remains an open question.
Interactions with other prescribed or unlicensed substances are typically not studied.

Regulatory note

No UK marketing authorisation as a medicine. Prohibited at all times under WADA S2 (peptide hormones, growth factors). The moment a UK seller or commentator makes a therapeutic claim, MHRA can treat the product as an unlicensed medicinal product.

Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.

Frequently asked questions

What is the evidence level for GHRP-6?

Phase 1 and Phase 2 early-development work in the 1990s. Did not progress to a licensed indication. Bulk of contemporary literature is preclinical growth-hormone-secretagogue pharmacology.

What is the UK regulatory status of GHRP-6?

No UK marketing authorisation as a medicine. Not controlled under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. WADA Prohibited List S2 (peptide hormones, growth factors), prohibited at all times.

Has GHRP-6 been tested in human clinical trials?

GHRP-6 has not been tested in phase II or phase III randomised human clinical trials with results published in the indexed peer-reviewed literature. The available evidence is preclinical (animal model or in vitro). PeptideClear publishes no dosing or human-use protocols.

Where can I read the source literature for GHRP-6?

The full PubMed search is linked above. Each cited paper has its title, author list and journal. Where we have a verified PMID or DOI the citation links directly. Other citations can be located by the reader through the journal index or the PubMed search.

Last verified 2026-05-22. Editorial commentary, not legal or clinical advice. Citations without a linked identifier can be located through the PubMed search and the journal index.